Nonclinical studies focus on which areas to support initial human dose?

• A. Marketing strategy and branding
• B. Safety studies, pharmacology, and toxicology
• C. Manufacturing capacity planning
• D. Patient recruitment targets

Answer: (B)

Nonclinical studies provide the data needed to justify a safe first-in-human dose. They evaluate how the drug acts (pharmacology), what adverse effects it may cause (toxicology and safety pharmacology), and how the drug moves through the body (pharmacokinetics/pharmacodynamics). This information helps translate animal data to humans and sets safe exposure levels and escalation plans for a first-in-human trial. The starting dose is typically derived from the no observed adverse effect level (NOAEL) with appropriate safety factors, or from pharmacology-based approaches like MABEL when pharmacologic activity guides dosing. Marketing strategy, manufacturing capacity planning, and patient recruitment targets do not inform dose selection; they address other aspects of development and trial conduct.